Health Care, 3 Other S&P Sectors at All-time Highs as Index Edges Closer to Fresh Peak
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Piper Ups Neurocrine to Overweight, Says '568 Still in the Game
Johnson & Johnson Seeks First Approval Of Nipocalimab To Treat Broadest Population Living With Antibody Positive Generalized Myasthenia Gravis
Tsinghua University's president has served as the chief scientist. Pinchi Medical has initiated IPO counseling, with investment from Gao Ling, Eli Lilly and Junlian.
1. Healthily Medical has initiated IPO counseling, with China International Capital Corporation as the consulting institution; 2. Healthily Medical's neuroregulation products such as brain pacemakers have broken the monopoly in the United States; 3. Healthily Medical's planned listing sector may be the STAR board.
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Bristol-Myers Squibb Analyst Ratings
'AHA Urges HRSA To Take Immediate Enforcement Action To Block J&J's Illegal Imposition Of 340B Rebate Model' - American Hospital Association
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Eli Lilly's self-operated website has launched a "small cup" weight loss drug, priced at only about half of the price of the base model.
Eli Lilly and Co. has announced that the low-dose version of Zepbound (telbivudine injection) has been launched in the USA. Patients can purchase it on Eli Lilly's self-operated website, LillyDirect. The price for a single dose of 2.5 milligrams is $399 for a four-week treatment, while the 5 milligram version is priced at $549, which is nearly a 50% discount from the original price.
FDA Approves Illumina's TruSight Oncology Biomarker Test
Dow Hits Closing High as Market Holds On to Records | Wall Street Today
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna